KRAS activating mutations have recently emerged as predictive biomarkers for treatment of CRC with EGFR inhibiting agents in clinical trials (Linardou et al, 2008; Riely and Ladanyi, 2008). This evidence concerns the gene EGFR and colorectal carcinoma.